The Doctors Company to buy medical insurer ProAssurance for about $1.3 billion
The Doctors Company, a medical malpractice insurer, said on Wednesday that it has entered into an agreement to acquire ProAssurance for about $1.3 billion.
ProAssurance Q4 Earnings Beat on Improved Net Investment Income
PRA's fourth-quarter earnings benefit from higher investment income and lower expenses, partially offset by lower premiums in the Specialty P&C segment.
ProAssurance Takes Defensive Play During Surge Of Jury Verdicts: Analyst
Citizens Capital Markets analyst Matthew J. Carletti reiterated the Market Outperform rating on ProAssurance Corporation PRA, with a price targe of $20.
ProAssurance Corporation (PRA) Q4 2024 Earnings Call Transcript
ProAssurance Corporation (PRA) Q4 2024 Earnings Call Transcript
Compared to Estimates, ProAssurance (PRA) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ProAssurance (PRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ProAssurance (PRA) Beats Q4 Earnings and Revenue Estimates
ProAssurance (PRA) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to loss of $0.05 per share a year ago.
Will Lower Premiums Earned Affect ProAssurance's Q4 Earnings?
PRA's fourth-quarter results are likely to have benefited from growing investment income and lower costs.
Stay Ahead of the Game With ProAssurance (PRA) Q4 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top -and-bottom-line estimates for ProAssurance (PRA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
ProAssurance (PRA) Upgraded to Buy: What Does It Mean for the Stock?
ProAssurance (PRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ProAssurance Q3 Earnings Beat on Strong Net Investment Income
PRA's third-quarter earnings benefit from improving underwriting results in its Specialty P&C segment. Declining profits in the Segregated Portfolio Cell Reinsurance unit partially offset the positives.
ProAssurance downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded ProAssurance to Neutral from Overweight with an unchanged price target of $18.
ProAssurance Corporation (PRA) Q3 2024 Earnings Call Transcript
ProAssurance Corporation (PRA) Q3 2024 Earnings Call Transcript
